PMA device
Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring System
Dexcom, Inc. · Sensor, Glucose, Invasive (MDS, Class III) · First FDA decision Feb 3, 2014, newest May 7, 2018Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
24
Naming "G4 Platinum"
MAUDE reports
95,859
Brand "G4 Platinum", since 2015
PubMed studies
64
Mentioning "G4 Platinum"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring SystemPMA supplement
P120005-S067 · Decided May 7, 2018 · 209 days after receipt · Normal 180 Day Track No User Fee
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
- DEXCOM G4 PLATINUM CONTINUOUS GLUCOSE MONITORING SYSTEM,DEXCOM G5 MOBILE CONTINUOUS GLUCOSE MONITORING SYSTEMPMA supplement
P120005-S042 · Decided Feb 5, 2016 · 73 days after receipt · Normal 180 Day Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
P120005-S031 · Decided May 22, 2015 · 177 days after receipt · Panel Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: P120005-S002
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "G4 Platinum", any status and sponsor, newest update first.
Medical University of GrazAcademic, hospital or other
NCT02614768 · 12 participants · Start Jul 2015 · Primary completion Aug 2015
Device: Glucose Sensor · For: Diabetes Mellitus, Type 1
Azienda Ospedaliero-Universitaria CareggiAcademic, hospital or other
NCT03557892 · 28 participants · Start Apr 1, 2018 · Primary completion Dec 20, 2019
Device: CGM+CSII; MDI with degludec · For: Diabetes Mellitus, Type 1
Sites: Florence, Italy
Yale UniversityAcademic, hospital or other
NCT02673203 · 31 participants · Start Feb 2016 · Primary completion Dec 14, 2017
Device: Continuous Glucose Monitoring System (CGMS) · For: Diabetes
Sites: New Haven, Connecticut · 2 sites in all
21 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "G4 Platinum", and for the whole product code for context.
This brand
95,859 reports: 93,771 malfunction, 1,973 injury, 113 death
Whole product code MDS
232,139 reports: 226,671 malfunction, 5,201 injury, 215 death
Newest reports for this brand
3004753838-2026-229026 · Received Aug 19, 2026 · Event dated Jul 31, 2026
Device type: Sensor, Glucose, Invasive (MDS)
Device problem as coded: Unexpected Shutdown
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004753838-2026-152891 · Received May 15, 2026 · Event dated May 6, 2026
Device type: Sensor, Glucose, Invasive (MDS)
Device problem as coded: Inappropriate or Unexpected Reset
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004753838-2025-102174 · Received Apr 30, 2025 · Event dated Apr 2, 2025
Device type: Sensor, Glucose, Invasive (MDS)
Device problem as coded: Defective Alarm
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1560-2020 · Started Feb 3, 2020
Reason given: The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems.
Cause as FDA categorized it: Under Investigation by firm · Device type: Sensor, Glucose, Invasive (MDS)
Z-1561-2020 · Started Feb 3, 2020
Reason given: The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems.
Cause as FDA categorized it: Under Investigation by firm · Device type: Sensor, Glucose, Invasive, Non-Adjunctive (PQF)
Published research
The most relevant PubMed records for "G4 Platinum"[tiab]. The summary above synthesizes these.
- Hypoglycemia event prediction from CGM using ensemble learning.
Fleischer J, Hansen TK, Cichosz SL · Front Clin Diabetes Healthc · 2022
- Continuous Glucose Monitoring in Healthy Children Aged 2-8 Years.
Sundberg F, Forsander G · Diabetes Technol Ther · 2018Research Support, Non-U.S. Gov't
- Evaluation of Reference Metrics for Continuous Glucose Monitoring in Persons Without Diabetes and Prediabetes.
Sofizadeh S, Pehrsson A, Ólafsdóttir AF, et al. · J Diabetes Sci Technol · 2022Research Support, Non-U.S. Gov't
- Continuous Glucose Monitor Interference With Commonly Prescribed Medications: A Pilot Study.
Basu A, Slama MQ, Nicholson WT, et al. · J Diabetes Sci Technol · 2017Clinical Trial, Research Support, Non-U.S. Gov't
- Continuous glucose monitoring in subjects undergoing bariatric surgery: Diurnal and nocturnal glycemic patterns.
Lupoli R, Lembo E, Ciciola P, et al. · Nutr Metab Cardiovasc Dis · 2020Comparative Study, Research Support, Non-U.S. Gov't
- Rationale and design of the Hyperglycemic Profiles in Obstructive Sleep Apnea (HYPNOS) trial.
Rooney MR, Aurora RN, Wang D, et al. · Contemp Clin Trials · 2021Research Support, N.I.H., Extramural, Clinical Trial Protocol
- Comparison of Continuous Glucose Monitoring Accuracy Between Abdominal and Upper Arm Insertion Sites.
Steineck IIK, Mahmoudi Z, Ranjan A, et al. · Diabetes Technol Ther · 2019Comparative Study, Research Support, Non-U.S. Gov't
- Analysis of "Simple Post-Processing of Continuous Glucose Monitoring Measurements Improves Endpoints in Clinical Trials".
Schmelzeisen-Redeker G · J Diabetes Sci Technol · 2020Comment
- Remote glucose monitoring in camp setting reduces the risk of prolonged nocturnal hypoglycemia.
DeSalvo DJ, Keith-Hynes P, Peyser T, et al. · Diabetes Technol Ther · 2014Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Usefulness and Safety of Remote Continuous Glucose Monitoring for a Severe COVID-19 Patient with Diabetes.
Ushigome E, Yamazaki M, Hamaguchi M, et al. · Diabetes Technol Ther · 2021Case Reports
- Modeling Transient Disconnections and Compression Artifacts of Continuous Glucose Sensors.
Facchinetti A, Del Favero S, Sparacino G, et al. · Diabetes Technol Ther · 2016Comparative Study
- Direct Evidence of Acetaminophen Interference with Subcutaneous Glucose Sensing in Humans: A Pilot Study.
Basu A, Veettil S, Dyer R, et al. · Diabetes Technol Ther · 2016Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code MDS.
- G5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2024
- FreeStyle Libre Pro Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2020
- Freestyle Navigator Continuous Glucose Monitoring SystemAbbott Laboratories · PMA 2011
- Paradigm Real-Time Insulin PumpMedtronic Minimed · PMA 2015
- Medtronic Minimed Continuous Glucose Monitoring SystemMedtronic Minimed · PMA 2011
- Guardian Connect SystemMedtronic Minimed · PMA 2025
- Dexcom Seven SystemDexcom, Inc. · PMA 2009
- Guardian RtMedtronic Minimed · PMA 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.